Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cravings

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    9 result(s) found for: Cravings. Displaying page 1 of 1.
    EudraCT Number: 2008-005363-34 Sponsor Protocol Number: EC/2008/50/FAHS Start Date*: 2009-03-10
    Sponsor Name:University of Surrey
    Full Title: Investigation to explore whether there is a synergistic effect between nicotine replacement therapy and guided bodyscanning on cigarette cravings and withdrawal symptoms in temporarily abstinent sm...
    Medical condition: Healthy volunteers who currently smoke 10 or more cigarettes per day, for the last 3 years. The trial intends to explore whether there is a synergistic effect between the relaxation technique of g...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10056484 Nicotine craving LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-004516-22 Sponsor Protocol Number: 04-4025 Start Date*: 2005-02-01
    Sponsor Name:Uppsala University
    Full Title: The impact of steroid hormones on symptom provocation in patients with premenstrual dysphoric disorder.
    Medical condition: Premenstrual Dysphoric Disorder
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-002203-40 Sponsor Protocol Number: 07.0056 Start Date*: 2007-10-03
    Sponsor Name:St. George's, University of London
    Full Title: Effect of hydrocortisone on desire to smoke and tobacco withdrawal symptoms
    Medical condition: Nicotine addiction; specifically, cortisol deficiency following smoking cessation.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10056478 Nicotine addiction LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-004463-37 Sponsor Protocol Number: 140682 Start Date*: 2016-06-20
    Sponsor Name:St. Olavs Hospital
    Full Title: ACUTE AND LONG-TERM EFFECTS OF INTRANASAL OXYTOCIN IN ALCOHOL WITHDRAWAL AND DEPENDENCE: A PROSPECTIVE RANDOMIZED PARALLEL GROUP PLACEBO-CONTROLLED TRIAL
    Medical condition: alcohol withdrawal and craving.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: View results
    EudraCT Number: 2019-002280-10 Sponsor Protocol Number: LBS180319 Start Date*: 2021-04-14
    Sponsor Name:St. Olav's University Hospital
    Full Title: Effects of intranasal oxytocin in the treatment of benzodiazepine withdrawal: A pilot randomized parallel group placebo-controlled trial
    Medical condition: Benzodiazepine withdrawal and craving
    Disease: Version SOC Term Classification Code Term Level
    20.0 10022891 - Investigations 10033329 Oxytocin PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-004692-36 Sponsor Protocol Number: VAR/01/011 Start Date*: 2011-11-30
    Sponsor Name:HOSPITAL UNIVERSITARI DE BELLVITGE
    Full Title: COMBIVAR. Randomized double-blind trial of two parallel groups design to evaluate the efficacy of smoking cessation with combined (varenicline plus nicotine patches) versus monotherapy (varenicline)
    Medical condition: NICOTINE DEPENDENCE.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10037175 - Psychiatric disorders 10032707 Other specified drug dependence, continuous use LLT
    14.0 10037175 - Psychiatric disorders 10012336 Dependence addictive LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-003035-35 Sponsor Protocol Number: HS-14-499 Start Date*: 2015-11-09
    Sponsor Name:Braeburn Pharmaceuticals
    Full Title: An Open-Label Multicenter Study Assessing the Long-Term Safety of a Once-Weekly and Once-Monthly, Long-Acting Subcutaneous Injection Depot of Buprenorphine (CAM2038) in Adult Outpatients with Opioi...
    Medical condition: Opioid Use Disorder
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) DK (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2014-002708-26 Sponsor Protocol Number: CRC341 Start Date*: 2017-06-28
    Sponsor Name:University of Surrey
    Full Title: A randomised double blind placebo controlled pilot trial of oxytocin efficacy in treating detoxified opioid dependent individuals
    Medical condition: Opioid dependence. The study will be investigating the efficacy of Syntocinon (oxytocin) on treating the withdrawal symptoms and cravings that opioid (e.g. almost always heroin) dependent individua...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10057379 Addiction relapse LLT
    20.0 100000004873 10001126 Addiction any drug LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-001997-70 Sponsor Protocol Number: EXCELLENCE/0421/0543v1 Start Date*: 2022-11-16
    Sponsor Name:University of Cyprus
    Full Title: Efficacy of Ketamine for the Prevention of Relapse in Patients with Opioid-Use Disorders (OUD)
    Medical condition: Methadone and buprenorphine comprise a first-line, evidence-based opioid substitution treatment (OST) for OUD patients. Unfortunately, retention and adherence to OST treatment is currently a major ...
    Disease: Version SOC Term Classification Code Term Level
    20.1 10037175 - Psychiatric disorders 10019935 Heroin addiction LLT
    20.1 10037175 - Psychiatric disorders 10030900 Opium addiction LLT
    20.0 10037175 - Psychiatric disorders 10012378 Depression PT
    21.1 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CY (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 01 22:31:00 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA